Long-read sequencing and de novo genome assembly data of Candida parapsilosis HMC1 and Rhodotorula mucilaginosa LBMH1012, two novel isolates with antifungal resistance signatures.

Candida parapsilosis and Rhodotorula mucilaginosa are opportunistic pathogens affecting mostly immunocompromised hosts. Both species have emerged as causes of invasive candidiasis and sepsis respectively. Here we present high-quality long-read genome assemblies for a strain of C. parapsilosis isolated from human breast milk, with multiple predicted signatures consistent with Candida Drug Resistance CDR1/CDR2 and Multi Drug Resistance MDR1-type genes, also for an environmental strain of R. mucilaginosa with multiresistance to azole antifungals. The genome sequencing was performed using the R9.4.1 flowcell with the MinION Mk1B sequencer (Oxford Nanopore Technologies, Oxford, UK). The draft genome of C. parapsilosis HMC1 was assembled from 85,745 long-reads and has 13,114,208 bp in length and comprises 10 contigs making it a highly contiguous assembly. The R. mucilaginosa LBMH1012 assembly has 23,636,156 bp in length and comprises 54 contigs. The genome completeness was estimated as 94.02 % and 91.40 % respectively using BUSCO. These data may be useful to explore the genetic diversity landscape in both species, infer potential causal genes for antifungal resistance and virulence, and represent an addition to the useful sequence space on emerging fungal pathogens.

Inhibition of Development and Metabolism of Dual-Species Biofilms of Candida albicans and Candida krusei (Pichia kudriavzevii) by Organoselenium Compounds.

Although Candida albicans is the most frequently identified Candida species in clinical settings, a significant number of infections related to the non-albicans Candida (NAC) species, Candida krusei, has been reported. Both species are able to produce biofilms and have been an important resistance-related factor to antimicrobial resistance. In addition, the microbial relationship is common in the human body, contributing to the formation of polymicrobial biofilms. Considering the great number of reports showing the increase in cases of resistance to the available antifungal drugs, the development of new and effective antifungal agents is critical. The inhibitory effect of Organoselenium Compounds (OCs) on the development of Candida albicans and Candida krusei was recently demonstrated, supporting the potential of these compounds as efficient antifungal drugs. In addition, OCs were able to reduce the viability and the development of biofilms, a very important step in colonization and infection caused by fungi. Thus, the objective of this study was to investigate the effect of the Organoselenium Compounds (p-MeOPhSe)2, (PhSe)2, and (p-Cl-PhSe)2 on the development of dual-species biofilms of Candida albicans and Candida krusei produced using either RPMI-1640 or Sabouraud Dextrose Broth (SDB) media. The development of dual-species biofilms was evaluated by the determination of both metabolic activity, using a metabolic assay based on the reduction of XTT (2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide sodium salt) assay and identification of either Candida albicans and Candida krusei on CHROMagar Candida medium. Biofilm formation using RPMI-1640 was inhibited in 90, 55, and 20% by 30 µM (p-MeOPhSe)2, (PhSe)2, and (p-Cl-PhSe)2, respectively. However, biofilms produced using SDB presented an inhibition of 62, 30 and 15% in the presence of 30 µM (p-MeOPhSe)2, (PhSe)2, and (p-Cl-PhSe)2, respectively. The metabolic activity of 24 h biofilms was inhibited by 35, 30 and 20% by 30 µM (p-MeOPhSe)2, (PhSe)2, and (p-Cl-PhSe)2, respectively, with RPMI-1640; however, 24 h biofilms formed using SDB were not modified by the OCs. In addition, a great reduction in the number of CFUs of Candida albicans (93%) in biofilms produced using RPMI-1640 in the presence of 30 µM (p-MeOPhSe)2 was observed. However, biofilms formed using SDB and treated with 30 µM (p-MeOPhSe)2 presented a reduction of 97 and 69% in the number of CFUs of Candida albicans and Candida krusei, respectively. These results demonstrated that Organoselenium Compounds, mainly (p-MeOPhSe)2, are able to decrease the metabolic activity of dual-species biofilms by reducing both Candida albicans and Candida krusei cell number during biofilm formation using either RPMI-1640 or SDB. Taken together, these results demonstrated the potential of the OCs to inhibit the development of dual-species biofilms of Candida albicans and Candida krusei.

Current Perspectives of Antifungal Therapy: A Special Focus on Candida auris.

Candida auris is an emerging Candida sp. that has rapidly spread all over the world. The evidence regarding its origin and emerging resistance is still unclear. The severe infection caused by this species results in significant mortality and morbidity among the elderly and immunocompromised individuals. The development of drug resistance is the major factor associated with the therapeutic failure of existing antifungal agents. Previous studies have addressed the antifungal resistance profile and drug discovery for C. auris. However, complete coverage of this information in a single investigation is not yet available. In this review, we have mainly focused on recent developments in therapeutic strategies against C. auris. Based on the available information, several different approaches were discussed, including existing antifungal drugs, chemical compounds, essential oils, natural products, antifungal peptides, immunotherapy, antimicrobial photodynamic therapy, drug repurposing, and drug delivery systems. Among them, synthetic chemicals, natural products, and antifungal peptides are the prime contributors. However, a limited number of resources are available to prove the efficiency of these potential therapies in clinical usage. Therefore, we anticipate that the findings gathered in this review will encourage further in vivo studies and clinical trials.

Analysis of epidemiological and clinical aspects in cases of fungal osteomyelitis caused by non-Candida species.

Osteomyelitis caused by non-Candida species is rare and often neglected, and current recommendations are based on primarily clinical experience and expert opinion. The objective of this study was to describe a case series of non-Candida fungal osteomyelitis. This retrospective study included 10 patients with non-Candida fungal osteomyelitis. Patients with osteomyelitis and microbiologically confirmed non-Candida species from bone fragment cultures were selected from the institution Infection Control Board database. Fusarium spp. were the most commonly isolated fungus from bone fragment cultures in five patients (50%). The majority did not present immunosuppression. The most common etiology was post-traumatic (n = 7, 70%), particularly open fractures. All patients were treated with antifungals associated with surgery. The antifungals used were itraconazole in five patients (50%), and voriconazole in another five patients (50%), with a median duration of antifungal therapy of four weeks (range: 3-25). There were no observed deaths within 30 days and one year. An antifungal approach combined with surgical treatment demonstrated favorable clinical outcomes, including low mortality rates and effective remission.

The Efficacy of Hybrid Vaginal Ovules for Co-Delivery of Curcumin and Miconazole against Candida albicans.

Curcumin (CUR) is a natural compound that can be combined with miconazole (MCZ) to improve vulvovaginal candidiasis (VVC) caused by Candida albicans treatment's efficacy. This study aimed to develop ureasil-polyether (U-PEO) vaginal ovules loaded with CUR and MCZ for the treatment of VVC. Physicochemical characterization was performed by thermogravimetry (TGA), differential thermal analysis (DTA), Fourier transform infrared spectroscopy (FTIR), and in vitro release. Antifungal assays were used to determine minimum inhibitory concentrations (MICs) and synergism between CUR and MCZ, and the activity of U-PEO ovules were performed by microdilution and agar diffusion. TGA results showed high thermal stability of the hybrid ovules. In DTA, the amorphous character of U-PEO and a possible interaction between CUR and MCZ were observed. FTIR showed no chemical incompatibility between the drugs. In vitro release resulted in 80% of CUR and 95% of MCZ released within 144 h. The MICs of CUR and MCZ were 256 and 2.5 µg/mL, respectively. After combining the drugs, the MIC of MCZ decreased four-fold to 0.625 µg/mL, while that of CUR decreased eight-fold to 32 µg/mL. Synergism was confirmed by the fractional inhibitory concentration index (FICI) equal to 0.375. U-PEO alone showed no antifungal activity. U-PEO/MCZ and U-PEO/CUR/MCZ ovules showed the greatest zones of inhibition (≥18 mm). The results highlight the potential of the ovules to be administered at a lower frequency and at reduced doses compared to available formulations.

Efeitos da terapia fotodinâmica mediada por curcumina livre e associada a nanopartículas de ferro sobre Candida spp. e biofilmes de estomatite protética / Effects of curcumin-mediated photodynamic therapy, alone and combined with Iron nanoparticles, on Candida spp. and prosthetic stomatitis biofilms

A estomatite protética é uma doença oral que resulta em processo inflamatório crônico da mucosa de suporte de uma prótese dentária, frequentemente associada à infecção por Candida. O tratamento da estomatite protética é dificultado pelo desenvolvimento de resistência das cepas de Candida aos fármacos antifúngicos. Neste cenário, este estudo teve como objetivo avaliar o efeito da terapia fotodinâmica antimicrobiana (TFDa) mediada por curcumina livre (CUR) e nanopartículas de ferro revestidas de curcumina (NpFeCUR) sobre Candida spp. Para isso, o estudo foi dividido em 2 etapas. Na etapa 1, os efeitos da TFDa mediada por NpFeCUR foi estudado sobre células planctônicas e biofilmes monoespécie da cepa de C. albicans SC5314. Após o tratamento com TFDa, as células viáveis foram quantificadas por contagem de Unidades Formadoras de Colônias (UFC). Os resultados dessa etapa demonstraram que a TFDa mediada por NpFeCUR não foi capaz de reduzir a viabilidade fúngica em culturas planctônicas e em biofilmes. Na etapa 2, foi avaliado o efeito da TFDa mediada por CUR sobre biofilmes formados a partir de amostras clínicas de estomatite protética. Essas amostras foram coletadas de 5 pacientes com estomatite protética e analisadas quanto à presença de Candida spp. pelo método de Gram e semeadura em Chromagar Candida. As espécies de Candida foram identificadas por meio de espectrometria de massa (MALDI-TOF). A seguir, a TFDa foi testada sobre biofilmes monoespécies das espécies de Candida isoladas e sobre os biofilmes microcosmos. Após a TFDa, as células viáveis foram determinadas pela contagem de UFC em meios de cultura não seletivo e seletivos para leveduras, estreptococos, estafilococos e estreptococos do grupo mutans. Nos resultados da etapa 2, foi encontrada a presença de Candida nas amostras clínicas de 3 pacientes (P1, P2 e P3). Nas amostras P1 e P3, foi identificada a espécie C. dubliniensis, já na amostra P2 foi encontrada C. albicans. Os biofilmes monoespécies dessas cepas apresentaram redução em torno de 3,0 log10 UFC após o tratamento com TFDa. Para os biofilmes microcosmos, a redução do número de UFC causada pela TFDa variou entre as amostras dos pacientes e os meios de cultura, sendo capaz de inibir o crescimento de microrganismos totais, leveduras, estreptococos, estreptococos do grupo mutans e estafilococos. Conclui-se que a TFDa mediada por NpFeCUR não apresentou atividade antifúngica contra C. albicans. Já a TFDa mediada por CUR foi eficaz na redução das espécies de Candida e biofilmes provenientes de lesões de estomatite protética.(AU)

Prosthetic stomatitis is an oral disease that results in a chronic inflammatory process of the supporting mucosa of a dental prosthesis, often associated with Candida infection. The treatment of prosthetic stomatitis is complicated by the development of resistance in Candida strains to antifungal drugs. In this scenario, this study aimed to evaluate the effect of antimicrobial photodynamic therapy (aPDT) mediated by free curcumin (CUR) and curcumin-coated iron nanoparticles (FeCUR NPs) on Candida spp. For this purpose, the study was divided into 2 stages. In stage 1, the effects of aPDT mediated by FeCUR NPs were studied on planktonic cells and monospecies biofilms of the C. albicans SC5314 strain. After aPDT treatment, viable cells were quantified by Colony-Forming Units (CFU) counting. The results of this stage demonstrated that aPDT mediated by FeCUR NPs was unable to reduce fungal viability in planktonic cultures and biofilms. In stage 2, the effect of aPDT mediated by CUR on biofilms formed from clinical samples of prosthetic stomatitis was evaluated. These samples were collected from 5 patients with prosthetic stomatitis and analyzed for the presence of Candida spp. by Gram staining and seeding on Chromagar Candida. Candida species were identified using mass spectrometry (MALDI-TOF). Subsequently, aPDT was tested on monospecies biofilms of the isolated Candida species and on microcosm biofilms. After aPDT, viable cells were determined by CFU counting on non-selective and selective culture media for yeasts, streptococci, staphylococci, and mutans group streptococci. In the results of stage 2, Candida was found in clinical samples from 3 patients (P1, P2, and P3). In P1 and P3 samples, C. dubliniensis was identified, while C. albicans was found in the P2 sample. Monospecies biofilms of these strains showed a reduction of around 3.0 log10 CFU after aPDT treatment. For microcosm biofilms, the reduction in CFU caused by aPDT varied between patient samples and culture media, being able to inhibit the growth of total microorganisms, yeasts, streptococci, mutans group streptococci, and staphylococci. It is concluded that aPDT mediated by FeCUR NPs did not exhibit antifungal activity against C. albicans. On the other hand, aPDT mediated by CUR was effective in reducing Candida species and biofilms from prosthetic stomatitis lesions.(AU)

Insights and Perspectives on the Role of Proteostasis and Heat Shock Proteins in Fungal Infections.

Fungi are a diverse group of eukaryotic organisms that infect humans, animals, and plants. To successfully colonize their hosts, pathogenic fungi must continuously adapt to the host's unique environment, e.g., changes in temperature, pH, and nutrient availability. Appropriate protein folding, assembly, and degradation are essential for maintaining cellular homeostasis and survival under stressful conditions. Therefore, the regulation of proteostasis is crucial for fungal pathogenesis. The heat shock response (HSR) is one of the most important cellular mechanisms for maintaining proteostasis. It is activated by various stresses and regulates the activity of heat shock proteins (HSPs). As molecular chaperones, HSPs participate in the proteostatic network to control cellular protein levels by affecting their conformation, location, and degradation. In recent years, a growing body of evidence has highlighted the crucial yet understudied role of stress response circuits in fungal infections. This review explores the role of protein homeostasis and HSPs in fungal pathogenicity, including their contributions to virulence and host-pathogen interactions, as well as the concerted effects between HSPs and the main proteostasis circuits in the cell. Furthermore, we discuss perspectives in the field and the potential for targeting the components of these circuits to develop novel antifungal therapies.

Prognostic Trends and Current Challenges in Candidemia: A Comparative Analysis of Two Multicenter Cohorts within the Past Decade.

Candidemia remains a major public health challenge due to its high mortality rates, especially in developing countries. Monitoring epidemiological trends may provide insights for better clinical outcomes. This study aimed to describe trends in the epidemiology, therapeutic practices, and mortality in candidemia through a retrospective comparative analysis between two surveillance cohorts of all candidemic adults at eleven tertiary hospitals in Brazil, from 2010-2011 (Period I) versus 2017-2018 (Period II). A total of 616 cases were diagnosed, with 247 being from Period II. These patients were more likely to have three or more coexisting comorbidities [72 (29.1%) vs. 60 (16.3%), p < 0.001], had a prior history of in-hospital admissions more often [102 (40.3%) vs. 79 (21.4%), p = 0.001], and presented with candidemia earlier after admission, within 15 days (0-328) vs. 19 (0-188), p = 0.01. Echinocandins were more frequently prescribed [102 (41.3%) vs. 50 (13.6%), p = 0.001], but time to antifungal initiation [2 days (0-14) vs. 2 (0-13), p = 0.369] and CVC removal within 48 h [90/185 (48.6%) vs. 148/319 (46.4%), p = 0.644] remained unchanged. Additionally, many patients went untreated in both periods I and II [87 (23.6%) vs. 43 (17.4%), p = 0.07], respectively. Unfortunately, no improvements in mortality rates at 14 days [123 (33.6%) vs. 93 (37.7%), p = 0.343] or at 30 days [188 (51.4%) vs. 120 (48.6%), p = 0.511] were observed. In conclusion, mortality rates remain exceedingly high despite therapeutic advances, probably associated with an increase in patients' complexity and suboptimal therapeutic interventions. Management strategies should be tailored to suit epidemiological changes, expedite diagnosis to reduce the number of untreated eligible patients and guarantee early antifungal initiation and source control.

Challenges, Characteristics, and Outcomes of Chronic Pulmonary Aspergillosis: A 11-Year Experience in A Middle-Income Country.

OBJECTIVES: Chronic pulmonary aspergillosis (CPA) is a research priority in fungal diseases with a need for new studies to reduce misdiagnosis with more common diseases, discuss improvement in diagnostic methods and better characterize gaps in antifungal and surgical treatments to improve clinical outcomes. METHODS: In this retrospective study, we reviewed medical records of patients diagnosed with CPA from January 2010 to June 2021 at University of São Paulo, São Paulo, Brazil. We evaluated clinical characteristics, radiological findings, serology, treatment, and outcomes. RESULTS: The study included 91 participants, with 43 (47.3%) patients who underwent surgery and 69 (75.8%) received antifungal therapy. We found a predominance of middle-aged adults (median 51 years), males (n = 58, 64%) with lower BMI (median 21.3 kg/m2). The most common underlying lung disease was pulmonary tuberculosis (n = 70, 76.9%). The commonest symptoms were cough (n = 67, 74%), haemoptysis, and dyspnea (n = 63, 70%). The most common chest computerized tomography abnormalities were cavity (n = 86, 94.5%), with a predominance of mycetomas (n = 78, 91%). The serology was positive in 81% (61/75). The one-year mortality was low (3.3%). Clinical improvement and stability occurred in 89% of participants for constitucional symptoms and 86% for pulmonary symptoms. While serological improvement and stability occurred in 71%. Radiological improvement and stability occurred in 75%. CONCLUSION: We observed a good outcome after 1-year follow-up, in which the majority had improvement or stability of pulmonary and constitutional symptoms, decrease in CIE titers and low mortality.

In Vitro Antifungal Activity of LL-37 Analogue Peptides against Candida spp.

Fungal infections have increased in recent decades with considerable morbidity and mortality, mainly in immunosuppressed or admitted-to-the-ICU patients. The fungal resistance to conventional antifungal treatments has become a public health problem, especially with Candida that presents resistance to several antifungals. Therefore, generating new alternatives of antifungal therapy is fundamental. One of these possibilities is the use of antimicrobial peptides, such as LL-37, which acts on the disruption of the microorganism membrane and promotes immunomodulatory effects in the host. In this study, we evaluated the in vitro antifungal activity of the LL-37 analogue peptides (AC-1, LL37-1, AC-2, and D) against different Candida spp. and clinical isolates obtained from patients with vulvovaginal candidiasis. Our results suggest that the peptides with the best ranges of MICs were LL37-1 and AC-2 (0.07 µM) against the strains studied. This inhibitory effect was confirmed by analyzing the yeast growth curves that evidenced a significant decrease in the fungal growth after exposure to LL-37 peptides. By the XTT technique we observed a significant reduction in the biofilm formation process when compared to yeasts untreated with the analogue peptides. In conclusion, we suggest that LL-37 analogue peptides may play an important antimicrobial role against Candida spp.

Alternative Splicing in Trichophyton rubrum Occurs in Efflux Pump Transcripts in Response to Antifungal Drugs.

Dermatophytes are challenging to treat because they have developed many strategies to neutralize the stress triggered by antifungals. Drug tolerance is achieved by mechanisms such as drug efflux and biofilm formation, and cellular efflux is a consequence of the synergistic and compensatory regulation of efflux pumps. Alternative splicing (AS) has also been considered as a mechanism that enhances fungal adaptive responses. We used RNA-seq data from the dermatophyte Trichophyton rubrum exposed to undecanoic acid (UDA) to search for and validate AS in genes encoding efflux pumps. The magnitude of this phenomenon was evaluated using UDA and other antifungals (caspofungin, itraconazole, and terbinafine) in planktonic and biofilm cultures. In addition to the conventional isoforms, the efflux pump encoded by TERG_04309 presented two intron-retained isoforms. Biofilms trigger the simultaneous production of at least two isoforms. The intron-retained isoforms showed short lengths and topologically different organization. Furthermore, we identified the putative interaction of efflux pumps (TERG_04309 and TERG_04224). Co-expression of these genes suggests a synergistic action in antifungal resistance. Our data provide new insights into drug tolerance related to differential isoform usage and the co-expression of stress-responsive genes, which may lead to higher antifungal resistance, mainly in biofilms.

A chloroacetamide derivative as a potent candidate for fusariosis treatment.

Fusariosis has presented a significant increase in their incidence in the last years. This epidemiological panorama probably is due to the increasing profile of refractory susceptibility of Fusarium spp. to available drugs, especially in immunocompromised individuals. Thus, the development of new compounds with effectiveness on these organisms is a necessity. This study evaluated the antifungal potential of a chloroacetamide derivative (4-BFCA) against resistant Fusarium strains. As a result, the compound was effective against all strains (MIC range 12.5-50 µg/mL). The time kill assay demonstrated that 4-BFCA presents a concentration-dependent fungicidal action. Although its action mechanism has not yet been elucidated, it was possible to observe its efficacy through damages and alterations provoked along the hyphae of Fusarium spp. 4-BFCA maintained a high survival rate of Tenebrio molitor larvae, suggesting that it does not cause acute systemic toxicity on this host at the concentration evaluated. In addition, 4-BFCA was 83.33% effective in combating a fungal infection in vivo on the chorioallantoid membrane of embryonated eggs. Our results are very promising and arouse interest to investigate the action of 4-BFCA on Fusarium strains since it acts as a possible candidate for the development of new therapies for the treatment of fusariosis.

Treatment of Human Sporotrichosis Caused by Sporothrix brasiliensis.

We describe the successful treatment of a series of 30 zoonotic sporotrichosis cases from southern Brazil. Sporothrix brasiliensis was the species genotypically identified in all 25 confirmed cases. Five other cases were classified as probable, without laboratory confirmation, but with clinical and epidemiological data of cat-transmitted sporotrichosis. Two isolates were sequenced by translation elongation factor-1 alpha (EF1α) loci in order to compare their sequences, and both of them showed distinct genotypes from S. brasiliensis strains from other Brazilian states. Itraconazole (ITZ) or potassium iodide (KI) were the first choice treatment in 28 and 2 cases, respectively. Microdilution assay showed a wild-type profile of S. brasiliensis isolates to ITZ. However, a lack of clinical response occurred in 42% of cases, especially those treated with ITZ 100 mg/day, and treatment needed modifications, by either increased doses or antifungal combinations. Clinical cure required a mean of 187 days of treatment, which was dependent on the clinical form of the disease and age of patients. Therapy, including dosages and durations, for cutaneous forms of sporotrichosis requires re-evaluation, since cases caused by S. brasiliensis may influence treatment efficacy.

Trichosporon inkin fungemia case report: clinical and laboratory management.

Trichosporon species are emerging as opportunistic pathogens that mainly affect immunocompromised patients. Patients with onco-hematological diseases usually present with fungemia by Trichosporon species, especially by T. asahii. Reports of this infection by other species of the genus are uncommon. Thus, in this paper, we present a case of T. inkin fungemia in a 39-year-old female patient with intestinal obstruction and absence of malignant hematological diseases. The late mycological diagnosis, the ineffective control of her pre-existing conditions and consequent failure to start antifungal therapy were the contributing factors for the patient's death.

Lay abstract Trichosporon species have been emerged as opportunistic fungi that mainly affect patients with low immunity. Hematological (blood related) cancer patients usually present with bloodstream infection with Trichosporon species, particularly Trichosporon asahii. Reports of this infection by other species of the genus are uncommon. Thus, in this paper, we present a case of bloodstream infection by Trichosporon inkin in a 39-year-old female patient with intestinal obstruction and absence of hematological cancer. The late fungal diagnosis, the ineffective control of the first symptoms and consequent failure to start specific medication were the factors that led to the patient's death.

Investigation of powerful fungicidal activity of tetra-cationic platinum(II) and palladium(II) porphyrins by antimicrobial photodynamic therapy assays.

This manuscript reports enhanced antimicrobial photoinactivation using tetra-cationic porphyrins with peripheral platinum(II) and palladium(II) complexes against fungal dermatophyte strains. Six different positively charged porphyrins were used and applied in antimicrobial photodynamic therapy experiments (aPDT) against dermatophyte fungi colonies. The microbiological tests were conducted with an adequate concentration of photosensitizer (PS) under white-light irradiation for 120 min and the most effective PS meta isomer 3PtP significantly reduced the concentration of viable fungal colony. In this way, tetra-cationic porphyrins containing platinum(II)-bipyridyl complexes may be promising fungicidal aPDT agents with potential applications in future clinical cases.

First report of cutaneous mycetoma by Paecilomyces variotii and the successful treatment with combined itraconazole and terbinafine along with resection surgeries.

Mycetoma is a progressively mutilating infectious disease of the subcutaneous tissue that affects the skin and deep structures, which is poorly responsive to chemotherapy. Here, we report a skin mycetoma caused by Paecilomyces variotii, an uncommon fungus of human infections, and the therapeutic approach that resulted in a complete cure of the patient.

[Optimization of variables in photodynamic antifungal assays against Candida species]. / Optimización de variables en ensayos de actividad antifúngica fotodinámica frente a especies de Candida.

Oral infections due to yeasts of the genus Candida are very common in patients with predisposing factors, such as physiological conditions or certain underlying diseases. Moreover, oral candidiasis can also evolve into disseminated forms. In this work, strains of the genus Candida were studied to establish the optimal radiation conditions for photosensitizing compounds, in a photodynamic antifungal therapy protocol. A total of 39 isolates were evaluated. The strains were exposed to twelve dyestuffs, eight radiation sources and three different exposure times. Orthotoluidine blue exhibited good photodynamic activity, in combination with exposure to a 20W reflector lamp LED (light-emitting diode) light for 60minutes. When considering the difficulties of using conventional antifungal drugs, the emergence of resistant strains, recurrences, and adverse reactions of certain commonly used drugs, the photodynamic antifungal therapy is a promising strategy for the treatment of localized infections.

(PhSe)2 and (pCl-PhSe)2 organochalcogen compounds inhibit Candida albicans adhesion to human endocervical (HeLa) cells and show anti-biofilm activities.

Adhesion capacity on biological surfaces and biofilm formation is considered an important step in the infection process by Candida albicans. The ability of (PhSe)2 and (pCl-PhSe)2, two synthetic organic selenium (organochalcogen) compounds, to act on C. albicans virulence factors related to adhesion to human endocervical (HeLa) cell surfaces and their anti-biofilm activities was analyzed. Both organochalcogen compounds inhibited C. albicans adhesion to HeLa cells, dependent on compound concentrations. (PhSe)2 (at 20 µM; p = 0.0012) was significantly more effective than (pCl-PhSe)2 (at 20 µM; p = 0.0183) compared with the control. (PhSe)2 inhibited biofilm formation and decreased biofilm viability in both early and mature biofilms more efficiently than (pCl-PhSe)2. Overall, the organochalcogen compounds, especially (PhSe)2, were demonstrated to be effective antifungal drugs against C. albicans virulence factors related to epithelial cell surface adhesion and the formation and viability of biofilms.

Thymomodulin in association with antifungal drugs in the therapy of cats with disseminated cutaneous sporotrichosis: a prospective study / Associação de timomodulina na terapia de gatos com esporotricose cutânea disseminada: um estudo prospectivo

ABSTRACT: Feline sporotrichosis is a relevant mycose in veterinary medicine due to its severity and zoonotic potential and the fact that it can be difficult to treat. The immune status of the animal exerts influence on the prognosis of the disease and determines its clinical outcome. This study evaluated the efficacy of the immunomodulatory thymomodulin as an adjunct to antifungal therapy in cats with disseminated sporotrichosis; thymomodulin was used in association with itraconazole (ITL) and potassium iodide (KI) to treat this fungal disease in the feline patient. Thirty-one cats (n=31) diagnosed with disseminated cutaneous sporotrichosis were divided into two groups as follows: Group 1 (G1) (n=16), which included those animals that were treated with thymomodulin in association with ITL and KI, and Group 2 (G2) (n=15) which had pacientsthat received ITL and KI only. The response to different treatment modalities was assessed, considering the survival rate, time frame for the lesions to respond to therapy, and clinical improvement or deterioration according to a body condition score system. Animals from G1 had a survival rate of nearly 100% (93.6%) that was approximately twice higher than the survival rate of those animals from G2 (53%). Moreover, patients from G1 had a significantly better prognosis, improved body condition, and shorter time for remission of the extra cutaneous clinical signs (p<0.02). Our findings showed that the association of thymomodulin with ITL and KI improves the prognosis of cats with disseminated cutaneous sporotrichosis.

RESUMO: A esporotricose é uma das micoses de maior relevância na medicina veterinária, tanto pela sua gravidade, seu potencial zoonótico e seu difícil tratamento. Sabe-se que o aspecto imunológico do gato representa um fator prognóstico determinante. O objetivo desse trabalho foi avaliar a eficácia do imunomodulador timomodulina como adjuvante a terapia antifúngica, itraconazol (ITL) com iodeto de potássio (KI), em gatos com esporotricose disseminada. Trinta e um gatos (n=31) com esporotricose cutânea disseminada foram segregados em dois grupos, o grupo 1 (G1) (n=16) tratado com ITL, KI associada à timomodulina e o grupo 2 (G2) (n=15) apenas ITL e KI. Foi avaliada a resposta clínica aos diferentes tratamentos, levando em consideração a taxa de sobrevivência, tempo de resposta das lesões e progressão do escore de condição corporal. O G1 apresentou taxa de sobrevivência de quase 100% (93,6%), aproximadamente o dobro do encontrado no G2 (53%). Mais que isso, o G1 demonstrou significativamente melhor prognóstico, aprimoramento do escore de condição corporal e menor tempo para remissão dos sinais clínicos extracutâneos (p<0,02). Sendo assim, a associação da timomodulina ao ITL e KI melhora o prognóstico de gatos com esporotricose cutânea disseminada.

Thymomodulin in association with antifungal drugs in the therapy of cats with disseminated cutaneous sporotrichosis: a prospective study / Associação de timomodulina na terapia de gatos com esporotricose cutânea disseminada: um estudo prospectivo

Feline sporotrichosis is a relevant mycose in veterinary medicine due to its severity and zoonotic potential and the fact that it can be difficult to treat. The immune status of the animal exerts influence on the prognosis of the disease and determines its clinical outcome. This study evaluated the efficacy of the immunomodulatory thymomodulin as an adjunct to antifungal therapy in cats with disseminated sporotrichosis; thymomodulin was used in association with itraconazole (ITL) and potassium iodide (KI) to treat this fungal disease in the feline patient. Thirty-one cats (n=31) diagnosed with disseminated cutaneous sporotrichosis were divided into two groups as follows: Group 1 (G1) (n=16), which included those animals that were treated with thymomodulin in association with ITL and KI, and Group 2 (G2) (n=15) which had pacientsthat received ITL and KI only. The response to different treatment modalities was assessed, considering the survival rate, time frame for the lesions to respond to therapy, and clinical improvement or deterioration according to a body condition score system. Animals from G1 had a survival rate of nearly 100% (93.6%) that was approximately twice higher than the survival rate of those animals from G2 (53%). Moreover, patients from G1 had a significantly better prognosis, improved body condition, and shorter time for remission of the extra cutaneous clinical signs (p 0.02). Our findings showed that the association of thymomodulin with ITL and KI improves the prognosis of cats with disseminated cutaneous sporotrichosis.(AU)

A esporotricose é uma das micoses de maior relevância na medicina veterinária, tanto pela sua gravidade, seu potencial zoonótico e seu difícil tratamento. Sabe-se que o aspecto imunológico do gato representa um fator prognóstico determinante. O objetivo desse trabalho foi avaliar a eficácia do imunomodulador timomodulina como adjuvante a terapia antifúngica, itraconazol (ITL) com iodeto de potássio (KI), em gatos com esporotricose disseminada. Trinta e um gatos (n=31) com esporotricose cutânea disseminada foram segregados em dois grupos, o grupo 1 (G1) (n=16) tratado com ITL, KI associada à timomodulina e o grupo 2 (G2) (n=15) apenas ITL e KI. Foi avaliada a resposta clínica aos diferentes tratamentos, levando em consideração a taxa de sobrevivência, tempo de resposta das lesões e progressão do escore de condição corporal. O G1 apresentou taxa de sobrevivência de quase 100% (93,6%), aproximadamente o dobro do encontrado no G2 (53%). Mais que isso, o G1 demonstrou significativamente melhor prognóstico, aprimoramento do escore de condição corporal e menor tempo para remissão dos sinais clínicos extracutâneos (p 0,02). Sendo assim, a associação da timomodulina ao ITL e KI melhora o prognóstico de gatos com esporotricose cutânea disseminada.(AU)